BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced a conference call and webcast to discuss regulatory ...

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDTBALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ...

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

In this video, Khalaf Bushara, MD, FRCP, highlights the greatest challenges in Friedreich's ataxia care and management.

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

Biogen Inc. (NASDAQ: BIIB) lost strength in Wednesday trading, after the Cambridge, Mass.-based company announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the ped ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with ...